June 20, 2019
Edesa Biotech continues testing potential dermatitis treatment EB01
Edesa Biotech may continue with its clinical investigation of potential treatment for chronic allergic contact dermatitis EB01, a novel sPLA2 inhibitor, after FDA’s approval.